Instrument Inactif

Autres langues Stemline Therapeutics, Inc.

Actions

US85858C1071

Recherche biotechnologique et médicale

Autres langues

14/06	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis
28/05	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer
25/05	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting
08/12	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
24/11	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS
20/03/25	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm
12/12/24	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela
11/12/23	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium
08/12/23	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023
20/11/23	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU
30/10/23	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
20/09/23	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
25/05/23	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study
09/05/23	Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
30/01/23	Stemline Therapeutics, Inc. Receives U.S. FDA Approval for ORSERDU
30/11/22	The Menarini Group and Stemline Therapeutics to Present Additional Data from the Phase 3 EMERALD Study of Elacestrant, an Investigational Oral SERD, During the Upcoming San Antonio Breast Cancer Symposium
11/08/22	Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
17/12/20	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy
10/06/20	Stemline Therapeutics, Inc. Announces Board Resignations
10/06/20	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
10/06/20	Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Global BMI Index
10/06/20	Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P TMI Index
10/06/20	Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Biotechnology Select Industry Index
10/06/20	Berlin-Chemie AG completed the acquisition of Stemline Therapeutics, Inc..
11/05/20	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)